Hurst said that evidence presented to date indicates that angioplasty will have a role in achieving improved stroke prevention, but stresses the importance of further study. The best hope of advancing that goal lies in carefully designed studies to rationally, and perhaps sequentially, evaluate the most appropriate role for the technique. Eric C. Raps, MD, director of the stroke and neurointensive care program, oversees the NACU, which has recently doubled its capacity from four to eight beds. The unit is staffed by experienced nurses and nurse practitioners who are specifically trained to provide optimal care for neurologic patients. Protecting the Brain from Stroke Damage Penn is participating in Phase III trials for four neuroprotective agents, which make the brain more tolerant of low blood flow, and protect it from damage caused by lack of oxygen and by the chemical reactions that occur in the injured brain tissue.
Preliminary studies are encouraging.
Patients presenting with acute ischemic stroke within six hours of the onset of symptoms will be considered for enrollment. Lubeluzole inhibits the production of nitric oxide, which accumulates and promotes brain injury. Patients who present with an acute ischemic stroke within eight hours of the onset of symptoms will be considered for enrollment. Cerestat is a novel neuroprotective agent designed to prevent or diminish secondary ischemic brain injury. It works by inhibiting glutamate induced brain injury.